Want to join the conversation?
$JNJ's Janssen Research & Development Phase 3 data presented for the first time at Digestive Disease Week 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving STELARA (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.